Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 18, Issue 5, 1996, Pages 975-980

  Porter, D L ^a,c   Roth, M S ^b   Lee, S J ^a   McGarigle, C ^a   Ferrara, J L M ^a   Antin, J H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adoptive immunotherapy; AML; Myelodysplasia; Relapsed leukemia

Indexed keywords

CYCLOSPORIN; CYTARABINE; HYDROXYUREA; INTERLEUKIN 2; METHOTREXATE; PREDNISONE;

ACUTE LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MALE; MONONUCLEAR CELL; MORTALITY; MYELODYSPLASIA; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029904695     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Mrsic M, Horowitz M, Atkinson K et al. Second HA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269-275.
2. Radich J, Sanders J, Buckner C et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11: 304-313.
3. Bar B, Schattenberg A, Mensink E et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11: 513-519.
4. Drobyski W, Keever C, Roth M et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
5. Helg C, Roux E, Beris P et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993; 12: 125-129.
6. Hertenstein B, Wiesneth M, Novotny J et al. Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 1993; 56: 1114-1118.
7. Kolb H, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
8. Porter D, Roth M, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100-106.
9. van Rhee F, Lin F, Cullis J et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
10. Porter D, Antin J. Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. Leuk Lymphoma 1995; 17: 191-197.
11. Kolb H, deWitte T, Mittermuller J et al. Graft-versus-leukemia effect of donor buffy coat transfusions on recurrent leukemia after marrow transplantation. Blood 1993; 82: (Suppl.): 840a.
12. Horowitz M, Gale R, Sondel P et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
13. Gale R, Horowitz M. Ash R et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120: 646-652.
14. Sullivan K, Weiden P, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
15. Naparsteck E, Or R, Nagler A et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506-515.
16. Szer J, Grigg A, Phillipos G, Sheridan W. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant 1993; 11: 109-111.
17. Ferster A, Bujan W, Mouraux T et al. Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. Bone Marrow Transplant 1994; 14: 331-332.
18. Collins R, Wolff S, List A et al. Prospective multicenter trial of donor buffy coat infusion for relapsed hematologic malignancy post-allogeneic bone marrow transplantation (BMT). Blood 1994; 84: 333a.
19. Vesole D, Tricot G, Jagannath S, Barlogie B. Induction of graft-versus-myeloma (GVM) effect following allogeneic bone marrow transplantation. Blood 1994; 84: 331a.
20. Pati A, Godder K, Lamb L et al. Donor leukocyte infusions (DLI) to treat relapsed acute myeloid leukemia (AML) following partially mismatched related donor (PMRD) bone marrow transplantation (BMT). Blood 1994; 84: 339a.
21. Porter D, Roth M, McGarigle C et al. The graft-vs-leukemia (GVL) effect of donor mononuclear cell (MNC) infusions for patients with relapsed acute leukemia and myelodysplasia (MDS) after allogeneic bone marrow transplantation. Blood 1994; 84: 338a.
22. Verfaillie C, Weisdorf D, McGlave P et al. High dose donor mononuclear cell infusion in post-transplant relapsed AML/MDS. Blood 1994; 84: 333a.
23. Takahashi S, Nagayama H, Nagamura F et al. Graft versus leukemia (GVL) effect with fatal graft versus host disease (GVHD) by donor leukocyte transfusion (DLT) in post-transplantation acute leukemia relapse: reports of two cases. Blood 1994; 84: 338a.
24. Slavin S, Or R, Kapelushnik Y et al. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT). Leukemia 1992; 6: 164-166.
25. Soiffer R, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994; 84: 964-971.
26. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
27. Shulman H, Sullivan K, Weiden P et al. Chronic graft-versus-host syndrome in man. A long-term clinico-pathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
28. Roth M, Antin J, Bingha E, Ginsburg D. Use of polymerase chain reaction-detected sequence polymorphisms to document engraftment following allogeneic bone marrow transplantation. Transplantation 1990; 49: 714-720.
29. Hendy G, Kronenberg H, Potts J, Rich A. Nucleotide sequence of cloned cDNAs encoding human preproparathyroid hormone. Proc Natl Acad Sci USA 1981; 78: 7365-7369.
30. Cullis J, Jiang Y, Schwarer A et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379-1380.
31. Porter D, Antin J. Adoptive immunotherapy in bone marrow transplantation. In: Burakoff S, Deeg H, Ferrara J (eds). Graft-versus-Host Disease. Marcel Dekker: New York, 1995.